Baseline Characteristics of Patients With RA Treated With ADA or TOF
RHEUMATOID ARTHRITIS, DISEASE
Abbreviations: ADA, adalimumab; b/tsDMARDs, biologic or targeted synthetic disease-modifying antirheumatic drugs; CRP, C-reactive protein; DAS28-CRP, disease activity score in 28 joints using C-reactive protein; EMR, electronic medical record; ESR, erythrocyte sedimentation rate; RA, rheumatoid arthritis; SJC28, swollen joint count based on 28-joint assessment; TJC28, tender joint count based on 28-joint assessment; TOF, tofacitinib.Data are presented as number (percentage) of patients unless otherwise indicated.Data were missing for 7 patients in the ADA group (1.2%) and 0 patients in the TOF group.Data were missing for 1 patient in the ADA group (0.2%) and 1 patient in the TOF group (0.4%).Data were missing for 1 patient in the ADA group (0.2%) and 0 patients in the TOF group.Data were missing for 68 patients in the ADA group (12.0%) and 40 in the TOF group (14.7%).Data were missing for 213 patients in the ADA group (37.4%) and 115 in the TOF group (42.1%).Data were missing for 75 patients in the ADA group (13.2%) and 45 in the TOF group (16.5%).Data were missing for 210 patients in the ADA group (36.9%) and 118 in the TOF group (43.2%).Data were missing for 217 patients in the ADA group (38.1%) and 120 in the TOF group (44.0%).After SBWs were applied, the standardized mean differences in baseline characteristics were between −0.03 and 0.03, within the conventional threshold of 0.1 for propensity score matching (